Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2019-06-26
Target enrollment:
Participant gender:
Summary
There is no standard treatment strategy for recurrent or metastatic esophageal squamous cell
carcinoma patients now, especially after the second-line treatment. Most of the patients have
the bad ECOG (Eastern Cooperative Oncology Group) score and prognosis. Chemotherapy,
radiotherapy, surgery are usually unacceptable for them. Previous data showed that apatinib
treatment significantly improved OS(overall survival) and PFS(progression-free survival) with
an acceptable safety profile in patients with advanced gastric cancer refractory to two or
more lines of prior chemotherapy. The study will observe the efficacy and safety of Apatinib
for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective,
single-arm, multicenter trial.